Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2,3-Bis-benzo[1,3]dioxol-5-ylmethyl-succinic acid** is a synthetic small molecule compound with the molecular formula C20H18O8 and a molecular weight of approximately 386.4 g/mol. It is primarily studied as an experimental inhibitor of metallo-beta-lactamases—specifically IMP-type enzymes found in antibiotic-resistant bacteria such as *Pseudomonas aeruginosa*. These enzymes hydrolyze beta-lactam antibiotics (including carbapenems), rendering them ineffective. This compound acts by binding to the active site of IMP-type metallo-beta-lactamases and inhibiting their enzymatic activity. Structural studies have shown it forms stable complexes with these enzymes and can protect broad-spectrum antibiotics from degradation in vitro. The compound has not been approved for clinical use and remains at the experimental research stage[1][2][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,3-bis-benzo[1,3]dioxol-5-ylmethyl-succinic acid.